Trial Profile
Single-center, Randomized, Double-blind, 2-treatment, 2-period Crossover Trial in Healthy Subjects to Demonstrate PK Bioequivalence and to Compare the PD Properties of Julphar Insulin N and Huminsulin Basal
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2020
Price :
$35
*
At a glance
- Drugs Insulin suspension isophane (Primary)
- Indications Diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Julphar Gulf Pharmaceutical Industries
- 01 Jul 2020 Status changed from active, no longer recruiting to completed.
- 26 Feb 2019 Planned End Date changed from 30 Apr 2018 to 30 Jul 2019.
- 26 Feb 2019 Planned primary completion date changed from 30 Apr 2018 to 30 Jul 2019.